Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF) PPT slides of all figures Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Wardenburg, J. B. Articles by Schneewind, O. Search for Related Content PubMed PubMed Citation Articles by Wardenburg, J. B. Articles by Schneewind, O. Pubmed/NCBI databases Substance via MeSH Related Collections Related Article Social Bookmarking                      What's this?

¹ Department of Microbiology and ² Department of Pediatrics, University of Chicago, Chicago, IL 60637

CORRESPONDENCE Olaf Schneewind: oschnee{at}bsd.uchicago.edu

Staphylococcus aureus pneumonia causes significant mortality in hospitalized or healthy individuals, and recent increases in morbidity are attributed to the rapid spread of methicillin-resistant S. aureus (MRSA) strains, which are often not susceptible to antibiotic therapy. -Hemolysin (Hla), a secreted pore-forming toxin, is an essential virulence factor of MRSA in a mouse model of S. aureus pneumonia. We show that the level of Hla expression by independent S. aureus strains directly correlates with their virulence. Active immunization with a mutant form of Hla (Hla_H35L), which cannot form pores, generates antigen-specific immunoglobulin G responses and affords protection against staphylococcal pneumonia. Moreover, transfer of Hla-specific antibodies protects naive animals against S. aureus challenge and prevents the injury of human lung epithelial cells during infection. Thus, Hla vaccination or immunotherapy may prevent S. aureus pneumonia in humans.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS